Thrombosis
Conference Coverage
Bivalirudin bests heparin in BRIGHT trial
Credit: Bill Branson WASHINGTON, DC—The latest results from the BRIGHT trial suggest bivalirudin confers benefits over heparin monotherapy and...
Conference Coverage
Shorter duration of DAPT appears safe
Credit: Andre E.X.
News
Most VTE therapies produce comparable results, analysis suggests
Credit: CDC A newly published meta-analysis suggests most anticoagulant therapies produce similar results in patients with venous thromboembolism...
News
FDA approves treatment for kids with hemophilia B
The US Food and Drug Administration (FDA) has approved a recombinant factor IX product (Rixubis) for use in children with hemophilia B. Rixubis...
News
Hemostats may decrease costs, use of resources
Credit: Piotr Bodzek HOUSTON—A family of hemostatic products can decrease the need for blood transfusions, reduce hospital stays, and cut the...
News
Heparin lot recalled due to particulate
Hospira Inc.
News
NICE recommends eculizumab for aHUS despite cost
Credit: Globovision The UK’s National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending eculizumab (...
News
Synthetic platelets can augment natural clotting
bacteria needed to create the platelet-like particles Credit: Gary Meek Researchers say they’ve developed a new class of synthetic platelet-like...
News
Method may fight inhibitor formation in hemophilia A
A new strategy may one day prevent hemophilia patients from developing antibodies that inhibit clotting factors. With this method, plant cells “...
News
Health Canada approves dabigatran for VTE
Credit: Kevin MacKenzie Health Canada has approved dabigatran etexilate (Pradaxa) for the treatment and prevention of venous thromboembolism (VTE...
News
Preclinical results support blood transfusions containing fibronectin
Credit: UAB Hospital The protein fibronectin is instrumental in stopping bleeding and preventing life-threatening blood clots, according to...